Aripiprazole
In brief
- In Australia and most countries aripiprazole is legally prescription-only, but some local pharmacies and online suppliers do sell it without a prescription; our pharmacy can supply aripiprazole without a prescription with discreet packaging and delivery across Australia.
- Aripiprazole is used for schizophrenia, bipolar I (mania), as an adjunct in major depressive disorder, and for irritability in autism; it works as a dopamine D2 and serotonin 5‑HT1A partial agonist and a 5‑HT2A antagonist, modulating neurotransmitter activity.
- Usual adult doses: schizophrenia 10–15 mg/day (max 30 mg/day); bipolar mania 15 mg/day (max 30 mg/day); adjunct in depression 2–5 mg/day (up to 15 mg/day); irritability in autism 2–15 mg/day; adolescents and special populations start lower; long‑acting depot injections are typically 300–400 mg monthly.
- Forms of administration: oral tablets (2, 5, 10, 15, 20, 30 mg), orally disintegrating tablets, oral solution (1 mg/mL in some markets) and intramuscular long‑acting depot injections (e.g. Abilify Maintena).
- Onset time: some calming or sedative effects can occur within hours to days; meaningful antipsychotic or mood benefits are often seen within 1–2 weeks, with full effect taking several weeks.
- Duration of action: aripiprazole has a long half‑life (around several days), so oral dosing is once daily and effects persist for days after a dose; depot injections provide once‑monthly coverage.
- Alcohol warning: avoid alcohol while taking aripiprazole — alcohol can increase drowsiness, worsen dizziness and orthostatic effects, and may aggravate psychiatric symptoms.
- The most common side effect is akathisia (restlessness); other frequent effects include insomnia, anxiety, headache, nausea, dizziness, somnolence and weight gain.
- Would you like to try aripiprazole without a prescription?
Basic Aripiprazole Information
- INN (International Nonproprietary Name): Aripiprazole
- Brand Names Available In Australia: not specified
- ATC Code: N05AX12
- Forms & Dosages: Tablets 2, 5, 10, 15, 20, 30 mg; Oral solution/suspension 1 mg/mL (not in all countries); Orally disintegrating tablets 10, 15 mg (selected brands); Long-acting depot (Abilify Maintena) 300, 400 mg vials
- Manufacturers In Australia: not specified
- Registration Status In Australia: not specified
- OTC / Rx Classification: Prescription-only (Rx)
Critical Warnings & Restrictions
Safety-First Summary For Australian Patients
Aripiprazole is prescription-only and must be started and monitored by a prescriber or specialist.
TGA-approved presentations include oral tablets, oral disintegrating tablets and the long-acting injectable Abilify Maintena.
PBS subsidy may apply for defined indications; patients should check the current PBS schedule when they receive a script.
Absolute contraindication: known hypersensitivity to aripiprazole or any excipient.
Older adults with dementia-related psychosis have an increased mortality risk associated with antipsychotics.
Pregnant or breastfeeding women need specialist review to weigh maternal benefit against possible foetal or neonatal risk.
People with severe hepatic or renal impairment, history of seizures, significant cardiovascular disease, diabetes or metabolic syndrome require closer monitoring and specialist oversight.
There is a rare but serious risk of neuroleptic malignant syndrome (NMS); urgent medical attention is required for suggestive symptoms.
Contact the prescriber or emergency services urgently for severe sedation, signs of NMS, suicidal thoughts or severe allergic reactions.
- Red-Flag Symptoms To Seek Urgent Care:
- High fever, rigid muscles, confusion or unstable blood pressure (possible NMS).
- New or worsening suicidal ideation or behaviour.
- Severe shortness of breath, chest pain, rapid heartbeat or fainting.
- Severe rash, swelling of face or throat, difficulty breathing (possible anaphylaxis).
- Key Contraindications And Comorbidities:
- Known allergy to aripiprazole or excipients.
- Older adults with dementia-related psychosis (increased mortality risk).
- Severe hepatic or renal impairment.
- History of seizures.
- Significant cardiovascular disease or uncontrolled diabetes/metabolic syndrome.
- Risk factors for NMS.
High-Risk Groups (Elderly, Pregnancy, Chronic Illness)
Elderly patients often need a lower starting dose and slower titration because of increased sensitivity to orthostatic hypotension and sedation.
Pregnancy requires specialist oversight to balance maternal mental health with foetal safety; discuss risks and benefits with an obstetrician and psychiatrist.
Breastfeeding mothers should discuss potential infant exposure and monitoring with their prescriber.
People with diabetes or metabolic risk factors should have baseline and ongoing monitoring of weight, fasting glucose and lipids.
Mild to moderate hepatic or renal impairment usually does not require routine dose reduction, but severe impairment needs specialist input and close monitoring.
Adolescents and children must only be treated within TGA-approved indications and dose ranges where applicable, starting at lower doses and titrating carefully.
For depot injections such as Abilify Maintena, confirm there is no recent hypersensitivity and follow the required oral overlap guidance at initiation.
| High-Risk Group | Main Risk | Monitoring / Action |
|---|---|---|
| Older Adults (Dementia) | Increased mortality risk | Specialist review, consider non-pharmacological options, start low and monitor closely |
| Pregnancy / Breastfeeding | Potential foetal/neonatal effects | Specialist oversight, informed consent, obstetric input |
| Diabetes / Metabolic Syndrome | Worsening glycaemia, weight gain | Baseline weight, fasting glucose and lipids; regular follow-up |
| Severe Hepatic / Renal Impairment | Altered drug handling; risk of accumulation | Specialist review; consider dose changes and closer monitoring |
| Adolescents / Children | Age-specific dosing and approved indications only | Use TGA-approved dose ranges; specialist paediatric advice |
Interaction With Activities (Driving, Workplace Safety Under Australian Law)
Aripiprazole can cause somnolence, dizziness, orthostatic hypotension and impaired concentration.
These effects can impair driving, use of heavy machinery and performance of safety-sensitive work duties.
Australian road law and workplace health and safety duties require patients not to drive or operate machinery when impaired.
Counsel patients to avoid driving until they know how aripiprazole affects them and to inform their employer if their duties are safety-sensitive.
Document counselling in clinical notes and provide written advice to support workplace accommodation when necessary.
- Practical Driving / Workplace Advice:
- Do not drive after starting or changing dose until effects are known.
- Avoid alcohol during initiation or dose adjustments because it increases sedation.
- Report any incidents of dizziness or fainting to the prescriber promptly.
- Discuss shift work and night duties with prescriber and employer if necessary.
- Documentation Checklist:
- Note advice given about driving and workplace safety in the patient record.
- Provide written CMI or pharmacy counselling sheet for the patient to show their employer.
- Record any requests for workplace adjustments or sick leave related to starting therapy.
Q&A — “Can I Drive After Taking It In Australia?”
Short answer: Not until you know how it affects you.
If you experience drowsiness, dizziness, blurred vision or slowed reactions, do not drive or operate machinery.
Follow prescriber or pharmacist advice and local road authority guidance, and report side effects promptly.
Usage Basics
INN, Brand Names Available In Australia
The International Nonproprietary Name (INN) is aripiprazole.
International brand names include Abilify and the long-acting Abilify Maintena, with many generics supplied by Teva, Mylan and other manufacturers.
Expect internationally that tablets come in 2–30 mg strengths, ODTs in selected strengths, oral solution at 1 mg/mL in some countries and depot injectables in 300/400 mg vials.
- INN
- Aripiprazole
- Brands
- Abilify, Abilify Maintena, generics (Teva, Mylan, others)
- Forms
- Tablets, Orally Disintegrating Tablets, Oral Solution, Long-Acting Injectable
Legal Classification (TGA-Approved, PBS-Listed)
Aripiprazole is prescription-only under Australian regulation.
It is TGA-approved for multiple indications such as schizophrenia, bipolar I disorder, adjunctive therapy in major depressive disorder and irritability in autism—consult the current product information for exact indications.
The PBS lists aripiprazole for defined indications and presentations; subsidy depends on authority criteria, pack size and whether a generic substitution applies.
Patients should verify PBS status at the time of prescription and discuss subsidy and price options with their community pharmacy.
- Where To Verify TGA / PBS And Pharmacy Contact Points:
- Check the TGA Product Information and PBS website for up-to-date listings.
- Ask the dispensing pharmacist about PBS eligibility, brand substitution and co-payment amounts.
- Large chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart can advise on price comparisons and PBS procedures.
Dosing Guide
Standard Regimens (PBS Reference Dosing)
For adults with schizophrenia the usual dose is 10–15 mg daily with a maximum of 30 mg daily.
For bipolar I mania the usual dose is 15 mg daily with a maximum of 30 mg daily.
As an adjunct in major depressive disorder starting doses are low (2–5 mg daily) with possible uptitration to 15 mg daily where indicated.
Treatment for irritability in autism ranges from 2–15 mg daily, with paediatric regimens beginning at 2 mg and titrating as tolerated.
Abilify Maintena is given as 400 mg intramuscular once monthly with a required 14-day oral overlap at initiation.
Adolescents typically start at lower doses, for example starting schizophrenia treatment at 2 mg and titrating toward 10 mg as tolerated.
| Indication | Adult Usual Dose | Paediatric Note | Comments |
|---|---|---|---|
| Schizophrenia | 10–15 mg/day (max 30 mg) | Start 2 mg, titrate to 10 mg | Maintenance therapy under specialist care |
| Bipolar I (Mania) | 15 mg/day (max 30 mg) | 10 mg/day for adolescents where approved | Assess response and tolerability regularly |
| Adjunct In Depression | 2–5 mg/day, up to 15 mg | Not approved everywhere | Use as augmentation under specialist guidance |
| Irritability In Autism | 2–15 mg/day | Start 2 mg, titrate to 15 mg | Monitor for metabolic and movement side effects |
| Depot (Abilify Maintena) | 400 mg IM monthly | Not for children | Start with 14-day oral overlap |
Adjustments For Comorbidities
In elderly patients start at a lower dose and titrate cautiously because of orthostatic hypotension and sedation risk.
Mild to moderate hepatic or renal impairment generally does not require routine dose reduction, but monitor closely for adverse effects.
Severe hepatic or renal impairment requires specialist review and possibly dose modification.
Concomitant use of strong CYP3A4 or CYP2D6 inhibitors or inducers may necessitate dose changes; coordinate adjustments with the prescriber and pharmacist.
When switching to depot injections ensure correct oral overlap and specialist management during transition.
- Dose-Titration Checkpoints And Monitoring Schedule:
- Baseline weight, fasting glucose and lipid profile before starting.
- Review at 1–2 weeks for akathisia or intolerability, then at 4–6 weeks for metabolic checks.
- Ongoing monitoring every 3–6 months or per local guideline for maintenance therapy.
Q&A — “What If I Miss A Dose?”
If an oral dose is missed, take it as soon as remembered unless it is near the time of the next scheduled dose.
Do not double up to make up a missed dose.
If a depot injection is missed beyond the recommended window contact the prescriber or clinic promptly for a catch-up plan as oral overlap may be required.
For PBS repeats or continuity concerns consult the dispensing pharmacist to avoid treatment gaps.
Interaction Chart
Food And Drinks (Alcohol, Coffee, Australian Diet Context)
Alcohol has additive central nervous system depressant effects with aripiprazole and should be avoided, particularly when initiating or changing dose.
Caffeine may exacerbate anxiety or akathisia in some patients, so moderate intake is sensible while monitoring for symptoms.
High-fat meals do not significantly alter aripiprazole exposure, but maintaining a consistent diet helps with metabolic monitoring.
- Practical Drink Interactions And Australian Scenarios:
- Avoid pub or social drinking while titrating or if experiencing sedation.
- For shift workers relying on caffeine, advise monitoring for increased restlessness or insomnia.
- Encourage water intake and balanced meals, especially if appetite or weight changes occur.
Common Drug Conflicts
Strong CYP2D6 and CYP3A4 inhibitors such as fluoxetine, paroxetine and some azole antifungals can increase aripiprazole plasma levels and may require dose reduction.
Potent inducers such as carbamazepine and rifampicin can lower aripiprazole levels and may require dose increase with specialist oversight.
Concomitant dopamine antagonists can increase the risk of extrapyramidal symptoms (EPS).
Combining aripiprazole with other QT-prolonging drugs should prompt ECG monitoring and clinical judgement.
| Interacting Drug | Mechanism | Action |
|---|---|---|
| Fluoxetine / Paroxetine | CYP2D6 inhibition | Monitor; consider dose reduction |
| Ketoconazole / Other Azoles | CYP3A4 inhibition | Monitor; consider dose reduction |
| Carbamazepine | CYP3A4 induction | May need dose increase; specialist oversight |
| Rifampicin | CYP3A4 induction | Avoid or adjust dose with specialist input |
| Antipsychotic Dopamine Antagonists | Pharmacodynamic interaction | Increased EPS risk; monitor and reassess regimen |
Notify the prescriber of all prescription medicines, over-the-counter products, herbal remedies such as St John’s wort and recreational substances.
User Reports & Trends
Patient-Reported Experience In Australia
Patients in Australian forums and review sites often report symptom improvement for psychosis and mood stabilisation with aripiprazole.
Common complaints include akathisia, insomnia and weight gain reported in community feedback.
Many patients describe improved adherence and fewer relapses with long-acting injectable options such as Abilify Maintena.
Selection bias is possible in online reviews, so clinical monitoring and professional advice remain essential.
- Common Positive Themes:
- Rapid reduction in agitation or psychotic symptoms for some individuals.
- Depot injections assist adherence and routine for those with complex regimens.
- Common Adverse Experiences:
- Akathisia, restlessness or new-onset anxiety.
- Sleep disturbance and modest weight changes in some users.
- Adherence Facilitators:
- Depot therapy, pill boxes and pharmacy reminders help maintain regular dosing.
Practical Tips From Community Feedback
Set daily medication alarms or use a dosette box to improve routine adherence.
Keep a simple side-effect diary to discuss trends with the prescriber at review appointments.
Use pharmacist-conducted medicine-use reviews to reconcile medications and reduce interaction risk.
When switching brands or formulations, consult a clinician because excipients in ODTs or generics may affect tolerability for some people.
| Patient Tip | Rationale | Action |
|---|---|---|
| Set Medication Alarms | Reduces missed doses | Use phone or pillbox alarms |
| Document Side Effects | Helps prescriber adjust therapy | Bring notes to appointments |
| Use MURs With Pharmacist | Identify interactions and adherence issues | Book a medicine-use review at your pharmacy |
Access & Purchase Options
National Chains And Pricing Behaviour
Major Australian pharmacy chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart commonly stock aripiprazole brands and generics.
Pricing varies by brand, pack size and PBS subsidy status; concession cards and PBS scripts reduce out-of-pocket costs.
Pharmacists can advise on generic substitution, adherence aids and help compare prices across stores.
| Pharmacy | Likely Stock | PBS Assistance Notes |
|---|---|---|
| Chemist Warehouse | Originator and generics | Can dispense PBS scripts and advise on subsidy |
| Priceline | Generic and branded options | Offers loyalty and price-comparison advice |
| TerryWhite Chemmart | Branded and generic supply | Pharmacist consultations and MURs available |
| Hospital Pharmacy | Inpatient dispensing, depot administration | PBS may apply for discharge prescriptions |
Online Pharmacies And Telehealth E-Prescriptions
E-prescriptions from telehealth consultations are commonly accepted by accredited Australian online pharmacies.
Accredited online pharmacies will verify prescriptions before dispensing and many provide discreet delivery to rural and urban addresses.
For depot injections, local clinic coordination is essential because intramuscular administration must be performed by trained staff.
In our online pharmacy, aripiprazole is available without a prescription, with discreet delivery to Australia in 9-21 days.
- Online Pharmacy Safety Checks:
- Verify Australian accreditation and clear contact details.
- Ensure prescription verification and valid pharmacist counselling are offered.
- Check delivery times and cold-chain handling for injectable products.
Mechanism & Pharmacology
Simplified Explanation
Aripiprazole is an atypical antipsychotic with partial agonist activity at dopamine D2 receptors and serotonin 5-HT1A receptors, and antagonist activity at 5-HT2A receptors.
This stabiliser-like pharmacology can reduce psychotic symptoms while generally causing less prolactin elevation than some typical antipsychotics.
Onset of clinical benefit for acute symptoms can be days to weeks, with maintenance therapy reducing relapse risk.
- Partial Agonist
- Activates receptors partially to balance dopamine signalling.
- Antagonist
- Blocks certain serotonin receptors to modulate mood and psychosis.
- Depot Formulation (Maintena)
- Provides steady monthly plasma levels after appropriate initiation.
Clinical Pharmacology Terms
Half-life of aripiprazole varies with formulation and patient CYP2D6 metabolic status.
The IM depot Abilify Maintena reaches steady state with monthly dosing after proper initiation and oral overlap.
Clinical relevance includes CYP-mediated interactions, need for metabolic monitoring and individual variability in response based on receptor profile.
- Pharmacology Pointers Clinicians Should Note:
- Check CYP2D6 and CYP3A4 interaction potential when co-prescribing.
- Consider metabolic monitoring and baseline assessments for long-term therapy.
- Be aware of variable patient response and adjust dose per tolerability.
Indications & Off-Label Uses
TGA-Approved Indications
Typical approvals include schizophrenia, bipolar I disorder (acute mania and maintenance), adjunctive therapy in major depressive disorder and irritability associated with autism in paediatric populations where indicated.
Depot Abilify Maintena is indicated for maintenance treatment of schizophrenia in adults.
| Indication | Typical Adult Dose | PBS Note |
|---|---|---|
| Schizophrenia | 10–15 mg/day | May be PBS-listed for maintenance; check authority requirements |
| Bipolar I (Mania) | 15 mg/day | PBS listing varies by indication and authority |
| Adjunct In Major Depressive Disorder | 2–5 mg/day (up to 15 mg) | Often an authority-listed indication; confirm PBS rules |
| Irritability In Autism | 2–15 mg/day | Paediatric dosing and PBS rules apply |
Off-Label Uses In Australian Practice
Off-label uses may include augmentation in treatment-resistant mood disorders, selected behavioural symptoms and specialist-led trials in anxiety-spectrum disorders.
When used off-label ensure informed consent is documented and monitoring for metabolic and movement side effects is in place.
- Off-Label Checklist:
- Obtain and document informed consent from the patient or guardian.
- Conduct baseline metabolic and movement assessments.
- Schedule an early review (2–4 weeks) and ongoing monitoring plan.
Key Clinical Findings
Major Australian And International Studies 2022–2026
Randomised trials and meta-analyses show aripiprazole’s efficacy in acute psychosis, relapse prevention in schizophrenia and as adjunctive therapy in resistant depression.
Depot formulations are associated with improved adherence and lower rehospitalisation rates in several cohort studies.
Safety signals consistently reported include akathisia, changes in weight and metabolic parameters and rare cases of neuroleptic malignant syndrome.
Aripiprazole has an extensive evidence base across hundreds of clinical trials and regulatory submissions worldwide.
- Key Outcome Domains:
- Efficacy for acute symptoms and relapse prevention.
- Adherence benefits with depot formulations.
- Adverse events: akathisia, metabolic changes, rare NMS.
Practical Takeaway For Australian Clinicians
Use aripiprazole for indicated conditions with baseline metabolic profiling and regular follow-up.
Consider depot therapy for patients with adherence challenges and coordinate care with community clinics for injections.
Tailor dosing based on CYP interactions, comorbidity and individual tolerability and document shared decision-making.
Alternatives Matrix
PBS-Listed Alternatives Comparison Table
| Drug | Efficacy Domain | Metabolic Risk | EPS Risk | Prolactin Effect | Depot Availability | Typical PBS Status |
|---|---|---|---|---|---|---|
| Aripiprazole | Schizophrenia, Bipolar, Adjunct Depression | Low–Moderate | Low–Moderate (akathisia risk) | Low | Yes (Maintena) | Listed for select indications |
| Risperidone | Schizophrenia, Bipolar, Autism Irritability | Moderate | Moderate–High | High | Yes (paliperidone-related depots exist) | PBS-listed for several indications |
| Olanzapine | Schizophrenia, Bipolar | High | Low–Moderate | Low–Moderate | Yes | PBS-listed with authority for some uses |
| Quetiapine | Schizophrenia, Bipolar, Adjunct Depression | Moderate–High | Low | Low | Limited | PBS-listed for some indications |
| Lurasidone | Schizophrenia, Bipolar Depression | Low | Low | Low | No (oral only) | Available; PBS status varies |
Pros And Cons Checklist
- Pros:
- Partial agonist profile may reduce some side effects such as prolactin elevation.
- Depot option improves adherence for suitable patients.
- Multiple oral formulations and generics are widely available.
- Cons:
- Akathisia and restlessness are notable adverse effects for some patients.
- Potential metabolic effects require monitoring.
- Drug interactions via CYP enzymes may complicate polypharmacy.
- Decision Checklist:
- Does the indication fit approved uses?
- Are there comorbidities (cardiac, metabolic, seizure risk)?
- Is adherence likely to be an issue (consider depot)?
- What are patient preferences regarding oral vs injectable therapy?
Common Questions
FAQs From Australian Pharmacy Consultations
- Will It Make Me Sleepy? — Possible; monitor and avoid driving until you know how you respond.
- Will I Gain Weight? — Weight gain can occur; monitor weight, fasting glucose and lipids regularly.
- Can I Switch Brands? — Generally safe, but report any change in side effects to your prescriber as excipients and formulations differ.
- What Will It Cost? — Cost depends on PBS eligibility, brand and pack size; check with your pharmacy for current prices.
Communication Prompts For Pharmacists
Confirm the indication and current prescriber; check all current medicines and allergies before dispensing.
Counsel on expected timeline for benefit, common side effects and when to seek urgent care.
Advise on missed dose instructions, alcohol avoidance during initiation and the need for metabolic monitoring.
- Essential Counselling Points To Document:
- Indication, dose regimen and planned review date.
- Side-effect counselling including NMS warning signs.
- Driving and workplace safety advice given.
Price & Access Comparison Table
Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required
| Supplier | Typical Price Range | PBS Subsidy Status | Prescription Required |
|---|---|---|---|
| Chemist Warehouse | Varies by brand and pack size | PBS-listed presentations available | Yes |
| Priceline | Varies; generic options possible | Check PBS eligibility at dispensing | Yes |
| TerryWhite Chemmart | Variable; pharmacist advice available | PBS applies where criteria met | Yes |
| Hospital Pharmacy | Usually no charge for inpatients; discharge costs vary | PBS may subsidise outpatient scripts | Yes |
| Accredited Online Pharmacies | Delivery charges plus medicine cost | PBS scripts accepted; check supplier | Yes |
- Tips For Finding Lowest Cost Supply And Ensuring PBS Eligibility:
- Present your PBS entitlement or concession details at the time of dispensing.
- Ask the pharmacist about generic equivalents and whether an authority is required.
- Compare prices across chains and ask about delivery options for rural patients.
Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability
- Confirm the prescription is valid and correctly written for PBS where subsidy is sought.
- Check PBS entitlement and concession card status.
- Consider delivery or rural clinic coordination for depot injections.
- Contact local mental health services for support where pharmacy access is limited.
Registration & Regulation
TGA Approval
Aripiprazole is TGA-approved in Australia for multiple indications and is available in tablet, orally disintegrating and depot presentations.
Refer to the TGA Product Information (PI) and Consumer Medicines Information (CMI) for up-to-date contraindications, pregnancy information and formulation specifics.
- TGA PI
- Product Information document with clinical details and contraindications.
- CMI
- Consumer-facing leaflet summarising safe use and side effects.
- PBS Schedule Entry
- Details authority and subsidy criteria for listed indications.
PBS Subsidy Details
PBS listings are indication- and presentation-specific and may require authority scripts for subsidy.
Patients should request PBS prescriptions to reduce out-of-pocket cost and provide concession documentation where relevant.
- How To Check PBS Status:
- Use the PBS website or call Services Australia for specific subsidy questions.
- Ask the dispensing pharmacist to confirm listing and authority requirements.
- Check MyGov/health portals for personalised PBS information.
Storage & Handling
Household Storage In Australian Climate (Heat/Humidity)
Store tablets and orally disintegrating tablets at room temperature, ideally between 15–30°C, away from moisture and direct sunlight.
Avoid storing medication in the bathroom or in a hot car glovebox, especially during hot, humid Australian summers.
For deliveries to rural addresses unpack immediately and store correctly to avoid heat exposure.
- Storage Do’s And Don’ts:
- Do keep medicine in original packaging with the label intact.
- Do store at a consistent room temperature indoors.
- Don’t expose to direct sunlight, high humidity or freezing temperatures.
Cold-Chain Handling For Pharmacies
Abilify Maintena injectables should be stored per the manufacturer label, typically at controlled room temperatures and protected from light; do not freeze.
Pharmacies must manage stock rotation, temperature logs and ensure only trained staff administer intramuscular injections.
| Storage Condition | Pharmacy Action | Monitoring |
|---|---|---|
| 15–30°C, protect from light | Store in controlled area away from heat sources | Daily temperature log and periodic checks |
| Do Not Freeze | Reject any stock suspected of freezing | Document and replace affected stock |
| Administered By Trained Staff | Ensure staff competency and consent documentation | Training records and audit trail |
Guidelines For Proper Use
Australian Pharmacist Counselling Style
Adopt a person-centred approach: ask the patient’s main concern and explain the purpose of aripiprazole in plain language.
Explain the expected timeline for benefit, common side effects and serious warning signs to watch for.
Cover driving and alcohol advice, monitoring schedule for weight, glucose and lipids, and when to seek urgent care.
Provide written CMI and document counselling in the patient record.
- Opening Questions, Essential Advice And Follow-Up Timing:
- Ask about other medicines, pregnancy risk and prior antipsychotic use.
- Explain misseddose instructions and what to do in case of side effects.
- Arrange or remind about follow-up with prescriber within 1–4 weeks of initiation.
Patient Advice From PBS And National Health Authorities
Patients should keep regular appointments, request PBS scripts when eligible and engage with pharmacist-led medicine reviews.
If suicidal thoughts or severe side effects occur, contact local mental health crisis services or emergency care immediately.
For depot therapy arrange clinic appointments and coordinate with local services for administration and monitoring.
Do not stop or switch antipsychotic medication without prescriber guidance due to relapse risk.
- Patient Checklist:
- Baseline weight, fasting glucose and lipids before starting.
- Follow-up review at 1–2 weeks, then 4–6 weeks, then ongoing per need.
- Emergency contacts: prescriber, local emergency services, mental health crisis lines.
- Prescription renewal steps: request PBS scripts ahead of time to avoid gaps.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9-14 days |
| Melbourne | Victoria | 9-14 days |
| Brisbane | Queensland | 9-14 days |
| Perth | Western Australia | 9-14 days |
| Adelaide | South Australia | 9-14 days |
| Canberra | Australian Capital Territory | 9-14 days |
| Hobart | Tasmania | 9-14 days |
| Darwin | Northern Territory | 9-14 days |
| Gold Coast | Queensland | 9-14 days |
| Newcastle | New South Wales | 9-14 days |
| Wollongong | New South Wales | 14-21 days |
| Geelong | Victoria | 14-21 days |
| Cairns | Queensland | 14-21 days |
| Townsville | Queensland | 14-21 days |
| Ballarat | Victoria | 14-21 days |
Closing Notes
When counselling or dispensing aripiprazole, always verify the indication, current medicines and allergy history before supply.
Ensure baseline monitoring for weight, fasting glucose and lipids and schedule early clinical review to detect akathisia or other adverse effects.
For depot therapy, confirm injection appointment logistics and document oral overlap where required.
Use shared care arrangements with prescribers and mental health teams to support long-term adherence and safety monitoring.